Charles River Laboratories
 
3Q Revenues:  $327.6 million (+12%)

3Q Earnings: $32.0 million (+4%)

YTD Revenues: $968.1 million (+10%)

YTD Earnings: $99.5 million (+19%)

Comments: Revenue growth was driven by the acquisition of Argenta and BioFocus, which was completed on April 1, 2014 and contributed 8% to 3Q revenue, as well as double-digit growth in the Manufacturing Support segment. Research Models and Services segment revenue was flat at $124.0 million in the quarter. Discovery and Safety Assessment revenue was $140.9 million, up 25% driven primarily by the acquisition of Argenta and BioFocus, which contributed 21%. Revenue for the Manufacturing segment was $62.7 million in the quarter, up 13%.